Combination Therapy with Atorvastatin and Amlodipine Suppresses Angiotensin II-Induced Aortic Aneurysm Formation

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Takahashi, Kikuyo ^a   Matsumoto, Yasuharu ^a   Do e, Zhulanqiqige ^a   Kanazawa, Masanori ^a   Satoh, Kimio ^a   Shimizu, Takuya ^a   Sato, Akira ^a   Fukumoto, Yoshihiro ^a   Shimokawa, Hiroaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN II; APOLIPOPROTEIN E; ATORVASTATIN; ELASTIN; MATRIX METALLOPROTEINASE; RHO KINASE; SODIUM CHLORIDE;

ABDOMINAL AORTA; ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN TISSUE; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; UPREGULATION;

AMLODIPINE; ANGIOTENSIN II; ANIMALS; AORTIC ANEURYSM, ABDOMINAL; APOPTOSIS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENZYME ACTIVATION; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; LIPIDS; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, KNOCKOUT; PYRROLES; RHO-ASSOCIATED KINASES;

EID: 84881487400     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072558     Document Type: Article

References (44)

1. Michel JB, Martin-Ventura JL, Egido J, Sakalihasan N, Treska V, et al. (2011) Novel aspects of the pathogenesis of aneurysms of the abdominal aorta in humans. Cardiovasc Res 90: 18-27. doi:10.1093/cvr/cvq337. PubMed: 21037321.
2. Golledge J, Norman PE, (2011) Current status of medical management for abdominal aortic aneurysm. Atherosclerosis 217: 57-63. doi:10.1016/j.atherosclerosis.2011.03.006. PubMed: 21596379.
3. Rashid M, Tawara S, Fukumoto Y, Seto M, Yano K, et al. (2009) Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors. Circ J 73: 361-370. doi:10.1253/circj.CJ-08-0817. PubMed: 19060417.
4. Mukai Y, Shimokawa H, Matoba T, Hiroki J, Kunihiro I, et al. (2003) Acute vasodilator effects of HMG-CoA reductase inhibitors: involvement of PI3-kinase/Akt pathway and Kv channels. J Cardiovasc Pharmacol 42: 118-124. doi:10.1097/00005344-200307000-00018. PubMed: 12827036.
5. Tada T, Nawata J, Wang H, Onoue N, Zhulanqiqige D, et al. (2008) Enhanced pulsatile pressure accelerates vascular smooth muscle migration: implications for atherogenesis of hypertension. Cardiovasc Res 80: 346-353. doi:10.1093/cvr/cvn211. PubMed: 18687705.
6. Schweitzer M, Mitmaker B, Obrand D, Sheiner N, Abraham C, et al. (2010) Atorvastatin modulates matrix metalloproteinase expression, activity, and signaling in abdominal aortic aneurysms. Vasc Endovasc Surg 44: 116-122. doi:10.1177/1538574409348352. PubMed: 20034937.
7. Twine CP, Williams IM, (2011) Systematic review and meta-analysis of the effects of statin therapy on abdominal aortic aneurysms. Br J Surg 98: 346-353. doi:10.1002/bjs.7343. PubMed: 21254006.
8. Miyake T, Morishita R, (2009) Pharmacological treatment of abdominal aortic aneurysm. Cardiovasc Res 83: 436-443. doi:10.1093/cvr/cvp155. PubMed: 19454489.
9. Bailey MA, Sohrabi S, Flood K, Griffin KJ, Rashid ST, et al. (2012) Calcium channel blockers enhance sac shrinkage after endovascular aneurysm repair. J Vasc Surg 55: 1593-1599. doi:10.1016/j.jvs.2011.12.075. PubMed: 22503181.
10. Kanematsu Y, Kanematsu M, Kurihara C, Tsou TL, Nuki Y, et al. (2010) Pharmacologically induced thoracic and abdominal aortic aneurysms in mice. Hypertension 55: 1267-1274. doi:10.1161/HYPERTENSIONAHA.109.140558. PubMed: 20212272.
11. Nordon IM, Hinchliffe RJ, Loftus IM, Thompson MM, (2011) Pathophysiology and epidemiology of abdominal aortic aneurysms. Nat. Rev Cardiol 8: 92-102. doi:10.1038/nrcardio.2010.180.
12. Wang Y, Ait-Oufella H, Herbin O, Bonnin P, Ramkhelawon B, et al. (2010) TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J Clin Invest 120: 422-432. doi:10.1172/JCI38136. PubMed: 20101093.
13. Ghoshal S, Loftin CD, (2012) Cyclooxygenase-2 inhibition attenuates abdominal aortic aneurysm progression in hyperlipidemic mice. PLOS ONE 7: e44369. doi:10.1371/journal.pone.0044369. PubMed: 23209546.
14. Cafueri G, Parodi F, Pistorio A, Bertolotto M, Ventura F, et al. (2012) Endothelial and smooth muscle cells from abdominal aortic aneurysm have increased oxidative stress and telomere attrition. PLOS ONE 7: e35312. doi:10.1371/journal.pone.0035312. PubMed: 22514726.
15. Satoh K, Nigro P, Matoba T, O'Dell MR, Cui Z, et al. (2009) Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med 15: 649-656. doi:10.1038/nm.1958. PubMed: 19430489.
16. Hellenthal FA, Buurman WA, Wodzig WK, Schurink GW, (2009) Biomarkers of abdominal aortic aneurysm progression. Part 2: inflammation. Nat. Rev Cardiol 6: 543-552. doi:10.1038/nrcardio.2009.102.
17. Shimokawa H, Takeshita A, (2005) Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 25: 1767-1775. doi:10.1161/01.ATV.0000176193.83629.c8. PubMed: 16002741.
18. Zhou Q, Liao JK, (2010) Pleiotropic effects of statins.- Basic research and clinical perspectives. Circ J 74: 818-826. doi:10.1253/circj.CJ-10-0110. PubMed: 20424337.
19. Das R, Burke T, Van Wagoner DR, Plow EF, (2009) L-type calcium channel blockers exert an antiinflammatory effect by suppressing expression of plasminogen receptors on macrophages. Circ Res 105: 167-175. doi:10.1161/CIRCRESAHA.109.200311. PubMed: 19520970.
20. Hata T, Soga J, Hidaka T, Idei N, Fujii Y, et al. (2011) Calcium channel blocker and Rho-associated kinase activity in patients with hypertension. J Hypertens 29: 373-379. doi:10.1097/00004872-201106001-01097. PubMed: 21063203.
21. Bruemmer D, Collins AR, Noh G, Wang W, Territo M, et al. (2003) Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest 112: 1318-1331. doi:10.1172/JCI200318141. PubMed: 14597759.
22. Matsumoto Y, Adams V, Jacob S, Mangner N, Schuler G, et al. (2010) Regular exercise training prevents aortic valve disease in low-density lipoprotein-receptor-deficient mice. Circulation 121: 759-767. doi:10.1161/CIRCULATIONAHA.109.892224. PubMed: 20124122.
23. Wang YX, Martin-McNulty B, da Cunha V, Vincelette J, Lu X, et al. (2005) Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis. Circulation 111: 2219-2226. doi:10.1161/01.CIR.0000163544.17221.BE. PubMed: 15851596.
24. Kaneko H, Anzai T, Takahashi T, Kohno T, Shimoda M, et al. (2011) Role of vascular endothelial growth factor-A in development of abdominal aortic aneurysm. Cardiovasc Res 91: 358-367. doi:10.1093/cvr/cvr080. PubMed: 21436157.
25. Tsuruda T, Kato J, Hatakeyama K, Kojima K, Yano M, et al. (2008) Adventitial mast cells contribute to pathogenesis in the progression of abdominal aortic aneurysm. Circ Res 102: 1368-1377. doi:10.1161/CIRCRESAHA.108.173682. PubMed: 18451339.
26. Matsumoto Y, Adams V, Walther C, Kleinecke C, Brugger P, et al. (2009) Reduced number and function of endothelial progenitor cells in patients with aortic valve stenosis: a novel concept for valvular endothelial cell repair. Eur Heart J 30: 346-355. PubMed: 19010796.
27. Do e Z, Fukumoto Y, Takaki A, Tawara S, Ohashi J, et al. (2009) Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension. Circ J 73: 1731-1739. doi:10.1253/circj.CJ-09-0135. PubMed: 19590140.
28. Satoh K, Fukumoto Y, Shimokawa H, (2011) Rho-kinase: important new therapeutic target in cardiovascular diseases. Am J Physiol Heart Circ Physiol 301: H287-H296. doi:10.1152/ajpheart.00327.2011. PubMed: 21622831.
29. Sukhija R, Aronow WS, Sandhu R, Kakar P, Babu S, (2006) Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol 97: 279-280. doi:10.1016/j.amjcard.2005.08.033. PubMed: 16442379.
30. Feeney JM, Burns K, Staff I, Bai J, Rodrigues N, et al. (2009) Prehospital HMG Co-A reductase inhibitor use and reduced mortality in ruptured abdominal aortic aneurysm. J Am Coll Surg 209: 41-46. doi:10.1016/j.jamcollsurg.2009.06.093. PubMed: 19651061.
31. Thompson A, Cooper JA, Fabricius M, Humphries SE, Ashton HA, et al. (2010) An analysis of drug modulation of abdominal aortic aneurysm growth through 25 years of surveillance. J Vasc Surg 52: 55-61 e52 doi:10.1016/j.jvs.2010.02.012. PubMed: 20620765.
32. Sweeting MJ, Thompson SG, Brown LC, Greenhalgh RM, Powell JT, (2010) Use of angiotensin converting enzyme inhibitors is associated with increased growth rate of abdominal aortic aneurysms. J Vasc Surg 52: 1-4. doi:10.1016/j.jvs.2010.05.066. PubMed: 20494541.
33. Baxter BT, Terrin MC, Dalman RL, (2008) Medical management of small abdominal aortic aneurysms. Circulation 117: 1883-1889. doi:10.1161/CIRCULATIONAHA.107.735274. PubMed: 18391122.
34. Hagita S, Osaka M, Shimokado K, Yoshida M, (2011) Combination of amlodipine and atorvastatin synergistically reduces leukocyte recruitment to mechanically injured mouse femoral artery. Hypertens Res 34: 450-455. doi:10.1038/hr.2010.254. PubMed: 21270816.
35. Kawai H, Deguchi S, Deguchi K, Yamashita T, Ohta Y, et al. (2011) Protection against ischemic stroke damage by synergistic treatment with amlodipine plus atorvastatin in Zucker metabolic rat. Brain Res 1382: 308-314. doi:10.1016/j.brainres.2011.01.062. PubMed: 21276424.
36. Suzuki J, Jin ZG, Meoli DF, Matoba T, Berk BC, (2006) Cyclophilin A is secreted by a vesicular pathway in vascular smooth muscle cells. Circ Res 98: 811-817. doi:10.1161/01.RES.0000216405.85080.a6. PubMed: 16527992.
37. Atkins GB, Jain MK, (2007) Role of Kruppel-like transcription factors in endothelial biology. Circ Res 100: 1686-1695. doi:10.1161/01.RES.0000267856.00713.0a. PubMed: 17585076.
38. Dua MM, Dalman RL, (2010) Hemodynamic influences on abdominal aortic aneurysm disease: Application of biomechanics to aneurysm pathophysiology. Vasc Pharmacol 53: 11-21. doi:10.1016/j.vph.2010.03.004. PubMed: 20347049.
39. Wang JA, Chen WA, Wang Y, Zhang S, Bi H, et al. (2011) Statins exert differential effects on angiotensin II-induced atherosclerosis, but no benefit for abdominal aortic aneurysms. Atherosclerosis 217: 90-96. doi:10.1016/j.atherosclerosis.2011.03.005. PubMed: 21481872.
40. Yagi S, Akaike M, Aihara K, Ishikawa K, Iwase T, et al. (2010) Endothelial nitric oxide synthase-independent protective action of statin against angiotensin II-induced atrial remodeling via reduced oxidant injury. Hypertension 55: 918-923. doi:10.1161/HYPERTENSIONAHA.109.146076. PubMed: 20194307.
41. Cassis LA, Gupte M, Thayer S, Zhang X, Charnigo R, et al. (2009) ANG II infusion promotes abdominal aortic aneurysms independent of increased blood pressure in hypercholesterolemic mice. Am J Physiol Heart Circ Physiol 296: H1660-H1665. doi:10.1152/ajpheart.00028.2009. PubMed: 19252100.
42. Stopher DA, Beresford AP, Macrae PV, Humphrey MJ, (1988) The metabolism and pharmacokinetics of amlodipine in humans and animals. J Cardiovasc Pharmacol 12 (Suppl 7):: S55-S59. doi:10.1097/00005344-198806124-00010. PubMed: 2467130.
43. Black AE, Sinz MW, Hayes RN, Woolf TF, (1998) Metabolism and excretion studies in mouse after single and multiple oral doses of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos 26: 755-763. PubMed: 9698289.
44. Cilla DD Jr., Whitfield LR, Gibson DM, Sedman AJ, Posvar EL, (1996) Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther 60: 687-695. doi:10.1016/S0009-9236(96)90218-0. PubMed: 8988072.